CRISPR Therapeutics reported Q4 2025 revenue of $54 million for CASGEVY, approved for SCD and TDT. 147 patients initiated treatment in 2025, with global expansion. Pediatric data showcased at ASH, leading to regulatory submissions for ages 5-11. In vivo liver editing advances with CTX310 targeting ANGPTL3 and CTX321 for Lp(a) program update in 2026.

CRISPR Therapeutics is advancing siRNA-based programs with CTX611 targeting FXI in a Phase 2 trial. Potential for thromboembolic indications in a multi-billion-dollar market. Leading Phase 3 development with Sirius Therapeutics. CRISPR Therapeutics has the option to nominate two siRNA targets for further research and development.

Zugocabtagene geleucel (zugo-cel) progresses in autoimmune disease and immuno-oncology. Phase 1 trials ongoing for SLE, SSc, inflammatory myositis, ITP, and wAIHA. Phase 1/2 trial in B-cell malignancies continues with updates expected in the second half of 2026. In vivo CAR-T platform advances supported by a GMP manufacturing facility in Massachusetts. CRISPR Therapeutics is progressing CTX213™, a beta cell replacement product for Type 1 diabetes, towards clinical trials. The company will present at upcoming events, including Citi’s 2026 Virtual Oncology Leadership Summit. In the fourth quarter of 2025, the company reported a net loss of $130.6 million, with $1,975.8 million in cash and equivalents.

CASGEVY® is a CRISPR/Cas9 gene-edited cell therapy approved for patients with SCD or TDT. The therapy reduces or eliminates VOCs for SCD patients and transfusion requirements for TDT patients. It was developed through a collaboration between CRISPR Therapeutics and Vertex, with Vertex leading global development and manufacturing.

CRISPR Therapeutics has a portfolio of in vivo programs, including CTX310, CTX340, and CTX321 for various cardiovascular conditions. Zugocabtagene geleucel (zugo-cel) is an allogeneic CAR-T cell therapy targeting CD19 for autoimmune and immuno-oncology indications. CTX611 is a double-stranded siRNA targeting FXI protein expression for anticoagulant effects, developed in collaboration with Sirius Therapeutics. CRISPR Therapeutics is advancing a diverse pipeline in gene editing, including hemoglobinopathies, cardiovascular, oncology, and rare diseases. The company is developing the SyNTase™ editing platform for precise gene correction. Strategic collaborations with Vertex Pharmaceuticals enhance CRISPR Therapeutics’ impact in gene editing. Headquartered in Zug, Switzerland, with U.S. operations in Boston and San Francisco.

CRISPR Therapeutics reports financial results with collaboration revenue of $35,000 in Q4 2025 and grant revenue of $864,000. Operating expenses include $83,526,000 in research and development costs. The company’s net loss for the period is $130,613,000. Cash and cash equivalents total $347,559,000, with total assets at $2,265,243,000. Total shareholders’ equity stands at $1,921,813,000. 1. The unemployment rate in the US dropped to 4.2% in September, the lowest since the start of the pandemic. This is a positive sign for the economy as more people are returning to work.

2. The stock market saw a significant increase today, with the Dow Jones Industrial Average rising by 300 points. This was driven by strong corporate earnings reports and optimism about the economic recovery.

3. In international news, the United Nations reported that over 10 million people are facing starvation in Afghanistan. The country is experiencing a severe humanitarian crisis due to the ongoing conflict and economic instability.

4. In technology news, Apple announced the release of its new iPhone 13, which features improved camera capabilities and longer battery life. The company expects strong sales for the new device.

5. Climate scientists issued a warning about the increasing frequency of extreme weather events, attributing them to climate change. They emphasized the urgent need for global action to reduce greenhouse gas emissions and mitigate the impact of climate change.

Read more at GlobeNewswire.: CRISPR Therapeutics Provides Business Update and Reports